Patents Issued in October 17, 2017
  • Patent number: 9789176
    Abstract: This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: October 17, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: Patrick M. Schlievert, Marnie L. Peterson
  • Patent number: 9789177
    Abstract: The present invention relates generally to novel recombinant polypeptides of Bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to Pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications including, but not limited to, applications in the context of conditions characterized by an aberrant, inappropriate or otherwise unwanted immune response to the Bahia grass pollen.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: October 17, 2017
    Assignee: Queensland University of Technology
    Inventors: Robyn O'Hehir, Janet Davies, Jennifer Rolland
  • Patent number: 9789178
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 17, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 9789179
    Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Patent number: 9789180
    Abstract: The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: October 17, 2017
    Assignee: The Regents of the University of California
    Inventors: Carolyn R. Bertozzi, Mary Sloan Siegrist Palmore, John C. Jewett, Chelsea G. Gordon, Peyton Shieh
  • Patent number: 9789181
    Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is H; X2 is selected from the group consisting of F, N, Y and W; X3 is H and X4 is selected from the group consisting of A, D and E. The invention also relates to large peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 17, 2017
    Assignee: EPIMMUNE INC.
    Inventors: Florence Dal Degan, Mark J. Newman, Jeffery L. Alexander, Scott Southwood
  • Patent number: 9789182
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 17, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Patent number: 9789183
    Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: October 17, 2017
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
  • Patent number: 9789184
    Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 17, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Gavin Thurston, Nicholas J. Papadopoulos
  • Patent number: 9789185
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: October 17, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 9789186
    Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 17, 2017
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
  • Patent number: 9789187
    Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 17, 2017
    Assignee: Cadila Pharmaceuticals Limited
    Inventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
  • Patent number: 9789188
    Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 17, 2017
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takuya Umemoto, Yuka Takagi, Yasunari Michinaka
  • Patent number: 9789189
    Abstract: Drug delivery compositions are provided having proteins and biodegradable polymers that may be used for controlled and long term release of proteins into a biological environment. According to some embodiments, the drug delivery composition may be provided with at least a protein and a biodegradable polymer possessing at least two different functional groups selected from the group of chosen among carboxyl, ester, amine, amide, thiol, thioester or hydroxyl groups pendant to the main polymer chain whereby the composition absorbs between 5-10% w/w water when exposed to physiological conditions for at least 20 days. A drug delivery system for controlled protein release which includes the drug delivery composition is also provided whereby the drug delivery system may be in the form of microparticles, films, coatings, fibers, pellets, cylinders, discs, implants, microcapsules, microspheres, nanospheres, wafers, micelles, liposomes or woven or non-woven fabrics.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: October 17, 2017
    Assignee: DSM IP ASSETS BV
    Inventors: Jens Christoph Thies, George Mihov, Guy Draaisma
  • Patent number: 9789190
    Abstract: Enamel Matrix Derivative (EMD) proteins and enamel matrix proteins are widely used in clinical dentistry because of their ability to promote regeneration of soft and hard tissues and to reduce inflammation and infections. The present invention relates to the surprising finding that a pharmaceutical, dental and/or cosmetic formulation, which comprises purified Enamel Matrix Derivative (EMD) proteins and/or enamel matrix proteins and sterilized Propylene Glycol Alginate (PGA), wherein the sterilized PGA is obtained from non-sterilized PGA having a weight average molecular weight (Mwo) of between 250-500 kDa, is more stable over time, especially, the pH is more stable over time.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: October 17, 2017
    Assignee: STRAUMANN HOLDING AG
    Inventors: Laszlo Garamszegi, Andri Vital
  • Patent number: 9789191
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: October 17, 2017
    Assignee: Solixa Technologies, Inc.
    Inventor: Kyle A. Reed
  • Patent number: 9789192
    Abstract: The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: October 17, 2017
    Assignee: Gruppo Farmaimpresa S.r.l.
    Inventor: Daniele Scetta
  • Patent number: 9789193
    Abstract: Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 17, 2017
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Shiladitya Sengupta, Ashish Kulkarni, Poornima Rao, Bhaskar Roy
  • Patent number: 9789194
    Abstract: Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: October 17, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, US ARMY, SECRETARY OF THE ARMY
    Inventors: David Devore, Charles Roth
  • Patent number: 9789195
    Abstract: Methods for efficient preparation of drug-polymer (or oligomer) conjugates useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications are provided. The invention also provides nanoparticles prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug). The method is particularly useful for formation of polymer/oligomer conjugates with drugs and other chemical species containing one or more hydroxyl groups or thiol groups.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: October 17, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Jianjun Cheng, Rong Tong
  • Patent number: 9789196
    Abstract: The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: October 17, 2017
    Assignee: ANTRIABIO, INC.
    Inventors: Kenneth Hinds, Danny Lewis, Paul Schmidt, Kathleen M. Campbell
  • Patent number: 9789197
    Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: October 17, 2017
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 9789198
    Abstract: Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules. The conjugates can interact with receptor dimers or polymers, thereby improving the in vivo distribution of the drug, changing the oil and water distribution coefficient, enhancing the pharmacological activity, reducing the blood-brain barrier permeability of the drug, and improving the bioavailability of the drug.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: October 17, 2017
    Assignee: JENKEM TECHNOLOGY CO., LTD. (TIANJIN)
    Inventors: Lihua Xu, Xuan Zhao, Zewang Feng, Jinliang Wang, Zhenguo Wang
  • Patent number: 9789199
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 17, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Patent number: 9789200
    Abstract: The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behavior is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: October 17, 2017
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Monica Campisi, Davide Renier, Pasquale Pierimarchi, Annalucia Serafino
  • Patent number: 9789201
    Abstract: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: October 17, 2017
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 9789202
    Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 17, 2017
    Assignees: HANMI SCIENCE CO., LTD., BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
  • Patent number: 9789203
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Patent number: 9789204
    Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: October 17, 2017
    Assignee: Immunogen, Inc.
    Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
  • Patent number: 9789205
    Abstract: Compositions and methods for transferring a nucleic acid to a target cell using an immune system cell are provided.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: October 17, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Alexander Kabanov, Elena Batrakova, Vivek Mahajan, Matthew J. Haney
  • Patent number: 9789206
    Abstract: Compounds, systems, and methods are provided for a non-invasive, analyte sensing dressing. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The device emits a detectable signal when the sensor is excited in the presence of the analyte. The sensor may include a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity is an indicator for oxygen concentration. An example metallated porphyrin has the Formula(I): wherein M is a metal, each R is independently an atom or a group of atoms, and at least one R is —OR1, wherein R1 is an atom or a group of atoms.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 17, 2017
    Assignee: The General Hospital Corporation
    Inventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
  • Patent number: 9789207
    Abstract: A PET imaging agent is made, by at first, washing out fluoride ions (F-18) adhered on an ion exchange resin to a reaction vessel with potassium carbonate/Kryptofix 2.2.2 in acetonitrile-water. After processing the first azeotropic distillation with helium while water is removed, the temperature is cooled down. Then, acetonitrile is added to the reaction vessel to be heated up. After processing the second azeotropic distillation with helium while water is removed, the temperature is cooled down and excess water is extracted. A precursor is then added to the reaction vessel to be heated up for processing a fluorination reaction. The reaction mixture obtained after the fluorination reaction is cooled down to be flown through a solid-phase extraction column with waste drained into a waste tank. Then, ethanol is used to wash out a product, i.e. [F-18]FEONM, adsorbed by the column, to be collected in a collection vial.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: October 17, 2017
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, Executive Yuan, R.O.C.
    Inventors: Li-Yuan Huang, Yean-Hung Tu, Jenn-Tzong Chen, Chyng-Yann Shiue
  • Patent number: 9789208
    Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: October 17, 2017
    Assignee: Purdue Research Foundation
    Inventor: Sumith A. Kularatne
  • Patent number: 9789209
    Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 17, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BERKE
    Inventors: Michael Page, Charles S. Craik
  • Patent number: 9789210
    Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 17, 2017
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
  • Patent number: 9789211
    Abstract: This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with 64Cu or 18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 17, 2017
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Peter S. Conti, Shuanglong Liu, Zibo Li
  • Patent number: 9789212
    Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: October 17, 2017
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Leonard F. Pease, Hedieh Saffari, Gerald J. Gleich, Kristin M. Leiferman, Kathryn A. Peterson, Russell Morris Condie
  • Patent number: 9789213
    Abstract: Polypeptides that target and/or bind to EGFL7 or its receptor and thereby reduce EGFL7 pro-angiogenic activity are provided. In this way, the polypeptides are, in an aspect, useful in the treatment of diseases, disorders, or conditions that involve pathological angiogenesis, such as, for example, cancer.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 17, 2017
    Assignee: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
    Inventors: John Lewis, Choi-Fong Cho, Leonard Luyt
  • Patent number: 9789214
    Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 17, 2017
    Assignees: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, NATIONAL YANG-MING UNIVERSITY
    Inventors: Hsin-Ell Wang, Chien-Chung Hsia, Mao-Chi Weng, Kun-Liang Lin, Hao-Wen Kao, Chao-Cheng Chen, Kwan-Hwa Chi, Der-Chi Tien, Wuu-Jyh Lin
  • Patent number: 9789215
    Abstract: Embodiments of the invention include an ultraviolet (UV) source, the UV source including a semiconductor device comprising an active layer disposed between an n-type region and a p-type region. The active layer emits radiation having a peak wavelength in a UV range. A reflector cup is disposed around the UV source. A transparent cover is disposed over the reflector cup.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 17, 2017
    Assignee: RayVio Corporation
    Inventors: Douglas A. Collins, Li Zhang, Yitao Liao
  • Patent number: 9789216
    Abstract: An aqueous disinfectant solution comprising peroxyacetic acid and a surfactant such as a polyoxyethylene alkyl ether phosphate, (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether) or cocoamidopropylamino oxide. The solution is preferably adjusted to provide a pH in the range 5-8 by a pH adjusting agent such as a phosphate buffer; hydroxide; carbonate; bicarbonate; a combination of carbonate and hydroxide; or a combination of carbonate and bi carbonate.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: October 17, 2017
    Assignee: Saban Ventures Pty Limited
    Inventors: Vladimir Berentsveig, Dipika Patel
  • Patent number: 9789217
    Abstract: The present invention refers to a Packaging and transportation kit for hydrogen peroxide or other chemical products used as sterilizing or disinfecting agents in sterilization or disinfection equipment that prevents leakage of the product. It also refers to the respective supplying system. The referred packaging and transportation kit comprises a primary recipient or a set of primary recipients (1, 12) made of material that is compatible with the chemical product used; a sealing membrane or nano-membrane (2.1); a separation membrane or nano-membrane (2.2) of the primary recipient (1, 12) that divides it into different parts; with or without a capsule (3) with one or more holes; a super absorbent material (4.1) applied around the recipient(s) (1); an absorbent material (4.2) that can be inserted in the interior of the recipient (1) together with the liquid; a chip/RFID with memory and/or color code system, and/or a barcode system, and/or a QR code system; a temperature and/or humidity indicator (6, 6.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 17, 2017
    Inventor: Helder Goncalves Da Costa
  • Patent number: 9789218
    Abstract: A phase change material is used for the production of a sterile state indication means for a sterilization container. A sterile state indication means for a sterilization container includes a fluid-tight case containing a phase change material. In this assembly, the case wall of the case includes at least one transparent zone and an activator which can be actuated in order to release an activation energy and/or crystallization seeds. The activator is in contact with the phase change material. Further, a sterilization container includes a container trough and a container lid, including a sterile state indication means. The sterile state indication means is provided either on the container trough or on the container lid, and the activator, in the closed state of the sterilization container, is in direct or indirect connection with the respectively other element among container trough and container lid.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 17, 2017
    Assignee: Aesculap AG
    Inventors: Corvin Motz, Gerold Zieris, Joachim Amann
  • Patent number: 9789219
    Abstract: A method of maintaining a desired level of an aerosolized compound within a space to be treated with the compound, the method including providing a diffusion device with the compound in liquid form and a control system for operating the device. The control system includes a sensor in fluid communication with the air within the space to be treated configured to sense the concentration of the compound aerosolized within the space. The diffusion device is operated to diffuse the compound into the space. The concentration of the compound within the space to be treated is sensed with the sensor and operation of the diffusion device is altered based on the concentration of the compound sensed to achieve a desired concentration of compound within the space. The sensing and operation altering steps are repeated periodically to maintain the desired concentration of the compound within the space.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: October 17, 2017
    Assignee: Prolitec Inc.
    Inventors: Craig Kelly, Richard W. Weening
  • Patent number: 9789220
    Abstract: The present invention provides for a disinfecting radiation base with a germicidal bulb for providing disinfecting radiation to a storage case for an ophthalmic lens, such as a contact lens. The disinfecting radiation base provides disinfecting radiation for disinfecting a contact lens. The disinfecting radiation base may also include a processor and digital memory for automated functions associated with the base.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 17, 2017
    Assignee: Johnson & Johnson Vision Care, Inc
    Inventors: Randall B Pugh, Edward R Kernick, William Chester Neeley, Dwight Abouhalkah, Leslie A Voss, Karson S Putt, James Daniel Riall
  • Patent number: 9789221
    Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 17, 2017
    Assignee: Mallinckrodt Pharma IP Trading D.A.C.
    Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wong
  • Patent number: 9789222
    Abstract: Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 17, 2017
    Assignee: SUNEVA MEDICAL, INC.
    Inventor: Louis Masi
  • Patent number: 9789223
    Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: October 17, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David Knaack, John Winterbottom, David R. Kaes, Todd M. Boyce, Lawrence A. Shimp
  • Patent number: 9789224
    Abstract: Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: October 17, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Karen Christman, Jennifer Singelyn, Jessica Dequach
  • Patent number: 9789225
    Abstract: Injectable bone graft material having a biocompatible, resorbable polymer and a biocompatible, resorbable inorganic material exhibiting macro, meso, and microporosities.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: October 17, 2017
    Assignee: Orthovita, Inc.
    Inventors: Charanpreet S. Bagga, Theodore D. Clineff, Erik M. Erbe, Michael W. Paris, Gina M. Nagvajara, Antony Koblish